anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University)

N/A

Report date: 2025/01/08 20:00:42

Base Information

Drug Nameanti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionAnti-BCMAFc receptor-like protein 5 modulatorsT lymphocyte replacements
TargetsB-cell maturation proteinFc receptor-like protein 5
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesXuzhou Medical University (Xzmu)
China Registration ClassN/A

Develop Information

Active CompaniesXuzhou Medical University (Xzmu)
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A